Premium
Benefit of extending the dosing interval of long‐acting antipsychotic injections on schizophrenics with extrapyramidal symptoms
Author(s) -
Suzuki Hidenobu,
Hibino Hiroyuki,
Inoue Yuichi,
Mikami Katsunaka
Publication year - 2017
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/pcn.12501
Subject(s) - akathisia , extrapyramidal symptoms , aripiprazole , antipsychotic , schizophrenia (object oriented programming) , dyskinesia , dosing , positive and negative syndrome scale , psychology , adverse effect , risperidone , medicine , tardive dyskinesia , psychiatry , anesthesia , psychosis , parkinson's disease , disease
O WING TO THE various adverse effects of antipsychotic drugs, including extrapyramidal symptoms (EPS) and cardiovascular diseases, due consideration must be given to minimizing their use in the maintenance phase. Antipsychotic drugs are given by tapering their dose, extending the dosing interval, and so forth, as part of a treatment strategy to minimize the adverse effects while at the same time maintaining efficacy. Here, we report two schizophrenia patients whose long-acting-injections (LAI) dosing intervals were extended from 4 weeks to 6 weeks after they became non-psychotic while undergoing LAI treatment, with the objective of observing their EPS. Two patients were assessed who fulfilled the following criteria for at least 3 months during LAI treatment with stable mental symptoms: (i) Positive and Negative